A single institution's experience with the treatment of localized primary @entity0 (PLB) was analyzed to understand the natural history of this disease and to identify major prognostic factors and optimal treatment. A retrospective analysis of 23 previously untreated @entity1 who met the strict criteria of PLB from 1972 through 1994 was undertaken. All pathologic materials were reviewed and classified by the Working Formulation. The Ann Arbor stages (AASs) were: IE, 17 @entity1 ; IIE, five @entity1 ; IV, one @entity1 (bilateral breast involvement without distant @entity3 ). Pathologic findings were: low grade, two @entity1 ; intermediate grade, 18 @entity1 (17 with @entity4812 ( @entity4812 )); high grade, two @entity1 ; and unclassifiable, one @entity1 . The treatments after biopsy or mastectomy were: radiation alone, two @entity1 ; chemotherapy alone, six @entity1 ; and combined-modality therapy, 13 @entity1 . Two @entity1 had mastectomy alone. @entity1349 ( @entity1349 ) and @entity4557 ( @entity4557 ) were calculated actuarially. Univariate analyses were performed with @entity1 age, treatment modality, @entity24293 , size of the @entity5 (T stage), and International Prognostic Index (IPI) for the 17 @entity1 with @entity4812 to define prognostic factors. The median follow-up for the surviving @entity1 was 78 months (range, 45-220 months). The 5-year @entity1349 and @entity4557 were 74% and 73%, respectively for all 23 @entity1 , and 65% and 70%, respectively, for the 17 @entity1 with @entity4812 . Statistically significant factors for @entity1349 for @entity4812 were @entity24293 and IPI. Statistically significant factors for @entity4557 were @entity24293 and T stage. With modern staging evaluation and multiagent combination chemotherapy, localized primary @entity1893 , especially diffuse large-cell type, has a prognosis as favorable as that of other @entity4812 . Ann Arbor stage was a significant factor for both @entity1349 and @entity4557 .

Localized primary XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['lymphoma of the breast'] @entity4557 :: ('MESH:D012008', 'Disease') :: ['RFS', 'relapse-free survival'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor'] @entity4812 :: ('MESH:D016403', 'Disease') :: ['DLCL', 'diffuse large-cell lymphoma'] @entity24293 :: ('MESH:C535331', 'Disease') :: ['AAS'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['non-Hodgkin lymphoma of the breast'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival']
@entity1893 :: (MESH:D008228,Disease) :: ['non-Hodgkin lymphoma of the breast']
